KR20200078425A - 재조합 변형된 섬유아세포 성장 인자 및 이의 치료적 용도 - Google Patents

재조합 변형된 섬유아세포 성장 인자 및 이의 치료적 용도 Download PDF

Info

Publication number
KR20200078425A
KR20200078425A KR1020197035895A KR20197035895A KR20200078425A KR 20200078425 A KR20200078425 A KR 20200078425A KR 1020197035895 A KR1020197035895 A KR 1020197035895A KR 20197035895 A KR20197035895 A KR 20197035895A KR 20200078425 A KR20200078425 A KR 20200078425A
Authority
KR
South Korea
Prior art keywords
polypeptide
modified fgf
corneal
seq
fgf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197035895A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 에벨리스
에벨리스 제니퍼 젠킨스
아무타칸난 수브라마니암
랄프 브래드쇼
Original Assignee
트레포일 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 트레포일 테라퓨틱스, 인크. filed Critical 트레포일 테라퓨틱스, 인크.
Publication of KR20200078425A publication Critical patent/KR20200078425A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1020197035895A 2017-05-05 2018-05-04 재조합 변형된 섬유아세포 성장 인자 및 이의 치료적 용도 Ceased KR20200078425A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762502529P 2017-05-05 2017-05-05
US201762502540P 2017-05-05 2017-05-05
US62/502,540 2017-05-05
US62/502,529 2017-05-05
US201762584624P 2017-11-10 2017-11-10
US62/584,624 2017-11-10
PCT/US2018/031189 WO2018204847A2 (en) 2017-05-05 2018-05-04 Recombinant modified fibroblast growth factors and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
KR20200078425A true KR20200078425A (ko) 2020-07-01

Family

ID=64016756

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197035895A Ceased KR20200078425A (ko) 2017-05-05 2018-05-04 재조합 변형된 섬유아세포 성장 인자 및 이의 치료적 용도

Country Status (12)

Country Link
US (2) US11479591B2 (enExample)
EP (2) EP4621067A3 (enExample)
JP (2) JP2020518287A (enExample)
KR (1) KR20200078425A (enExample)
CN (1) CN111148755A (enExample)
AU (1) AU2018261021B2 (enExample)
BR (1) BR112019023260A2 (enExample)
CA (1) CA3062473A1 (enExample)
DK (1) DK3619324T3 (enExample)
ES (1) ES3041527T3 (enExample)
MX (1) MX2019013210A (enExample)
WO (1) WO2018204847A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021261946A1 (ko) 2020-06-26 2021-12-30 엘티소재주식회사 헤테로고리 화합물 및 이를 이용한 유기 발광 소자

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4621067A3 (en) 2017-05-05 2025-11-19 Trefoil Therapeutics, Inc. Recombinant modified fibroblast growth factors and therapeutic uses thereof
JP2023532046A (ja) * 2020-06-26 2023-07-26 トレフォイル セラピューティクス，インク． 組換え修飾線維芽細胞増殖因子およびそれを使用した治療
WO2022241465A1 (en) * 2021-05-14 2022-11-17 Claris Biotherapeutics, Inc. Compositions of growth factor for the treatment of eye disease
CN113289005B (zh) * 2021-07-06 2022-05-31 温州医科大学 rhFGF-21在制备治疗干眼症药物中的应用
WO2023019218A1 (en) * 2021-08-12 2023-02-16 Trefoil Therapeutics, Inc. Modified fibroblast growth factors for treating fibrotic diseases
US12357843B2 (en) 2022-03-25 2025-07-15 Cutera, Inc. Methods of skin treatment with laser light
CN115177717A (zh) * 2022-08-31 2022-10-14 贵州医科大学附属医院 一种治疗眼表及角膜上皮疾病的药物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552528A (en) * 1986-03-03 1996-09-03 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bovine b-endothelial cell growth factor
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
GB2223496B (en) * 1988-08-08 1992-05-27 British Bio Technology Synthetic gene encoding mature human acid fibroblast growth factor
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
GB9523946D0 (en) 1995-11-23 1996-01-24 Bayer Ag Leukotriene antagonistic benzoic acid derivatives
US20010006939A1 (en) 1997-10-03 2001-07-05 Ralph W. Niven Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
US6642026B2 (en) * 2000-08-15 2003-11-04 Phage Biotechnology Corporation Method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis
AU1628101A (en) 1999-11-22 2001-06-04 Millennium Pharmaceuticals, Inc. Jaffa, a novel fibroblast growth factor family member and uses therefor
WO2005048942A2 (en) 2003-11-13 2005-06-02 Pharmacia Corporation Combination therapy comprising a cox-2 inhibitor and an antineoplastic agent
US7790682B1 (en) 2003-12-02 2010-09-07 The Florida State University Research Foundation, Inc. Engineered human acidic fibroblast growth factors and associated methods
BRPI0416683A (pt) * 2003-12-10 2007-01-30 Lilly Co Eli muteìna de fator de crescimento de fibroblasto de humano 21 (fgf-21), ou um seu peptìdeo biologicamente ativo, polinucleotìdeo, vetor de expressão, célula hospedeira, processo para produzir um polipeptìdeo, composição farmacêutica, método para tratar um paciente, e, uso da muteìna fgf-21
EP1634877B1 (en) * 2004-08-17 2011-06-22 Simpson Biotech Co., Ltd. Mixture and compounds from mycelia of antrodia camphorata and use thereof
US7595296B1 (en) 2006-11-09 2009-09-29 Florida State University Research Foundation, Inc. Mutant polypeptides of fibroblast growth factor 1
US7659379B1 (en) 2007-05-24 2010-02-09 Florida State University Research Foundation, Inc. Mutants of human fibroblast growth factor having increased stability and/or mitogenic potency
NZ601868A (en) * 2008-01-22 2014-05-30 Araim Pharmaceuticals Inc Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
US8461111B2 (en) 2009-05-20 2013-06-11 Florida State University Research Foundation Fibroblast growth factor mutants having improved functional half-life and methods of their use
US20110224404A1 (en) 2010-03-11 2011-09-15 Florida State University Research Foundation Method for development of a peptide building block useful for de novo protein design
US9006400B2 (en) * 2011-09-26 2015-04-14 Novartis Ag Fibroblast growth factor-21-Fc fusion proteins
US20150253308A1 (en) * 2013-05-03 2015-09-10 Orasis Compositions and methods of treating glaucoma
WO2015048188A2 (en) * 2013-09-25 2015-04-02 Trefoil Therapeutics, Llc Modified fibroblast growth factors for the treatment of ocular disorders
TWI634898B (zh) * 2013-10-07 2018-09-11 雅祥生技醫藥股份有限公司 經修飾之人類酸性纖維母細胞生長因子及其組合物
US20150104494A1 (en) * 2013-10-11 2015-04-16 Ohio State Innovation Foundation Methods for repair of ear canal tissue defects
JP6621752B2 (ja) 2013-10-21 2019-12-18 ソーク インスティテュート フォー バイオロジカル スタディーズ 変異した線維芽細胞増殖因子（ｆｇｆ）１および使用方法
WO2015198175A1 (en) 2014-06-27 2015-12-30 Florida State University Research Foundation, Inc. Design of fgf-1 mutants to effectively eliminate reactive cysteine residues
WO2016172153A2 (en) 2015-04-20 2016-10-27 Salk Institute For Biological Studies Fibroblast growth factor (fgf) 1 with mutation in the heparin binding domain and methods of use to reduce blood glucose
CA2983268A1 (en) * 2015-04-20 2016-10-27 Salk Institute For Biological Studies Fibroblast growth factor (fgf) 1 mutants and methods of use to reduce blood glucose
EP3336178B1 (en) * 2015-08-13 2020-03-18 Fujifilm Corporation Method for culturing pluripotent stem cells, method for manufacturing culture vessel, culture vessel, and scaffold material for culturing cells
EP4621067A3 (en) 2017-05-05 2025-11-19 Trefoil Therapeutics, Inc. Recombinant modified fibroblast growth factors and therapeutic uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021261946A1 (ko) 2020-06-26 2021-12-30 엘티소재주식회사 헤테로고리 화합물 및 이를 이용한 유기 발광 소자

Also Published As

Publication number Publication date
AU2018261021B2 (en) 2024-09-12
US11479591B2 (en) 2022-10-25
JP2020518287A (ja) 2020-06-25
EP3619324A2 (en) 2020-03-11
ES3041527T3 (en) 2025-11-12
EP3619324B1 (en) 2025-07-09
US20230130851A1 (en) 2023-04-27
MX2019013210A (es) 2020-07-20
BR112019023260A2 (pt) 2022-02-22
RU2019139358A (ru) 2021-06-07
US20200190158A1 (en) 2020-06-18
DK3619324T3 (da) 2025-09-22
CA3062473A1 (en) 2018-11-08
JP2024112824A (ja) 2024-08-21
WO2018204847A2 (en) 2018-11-08
EP4621067A3 (en) 2025-11-19
EP3619324A4 (en) 2020-12-30
RU2019139358A3 (enExample) 2021-08-26
AU2018261021A1 (en) 2019-12-12
CN111148755A (zh) 2020-05-12
EP4621067A2 (en) 2025-09-24

Similar Documents

Publication Publication Date Title
US20230130851A1 (en) Recombinant modified fibroblast growth factors and therapeutic uses thereof
US20240024421A1 (en) Recombinant modified fibroblast growth factors and therapeutic uses thereof
US20210338777A1 (en) Modified fibroblast growth factors for the treatment of ocular disorders
JP6755856B2 (ja) ランピルナーゼを含有する局所組成物
KR20190093626A (ko) 황반변성의 신규 치료 방법
KR20220079860A (ko) 신규 펩티드
US20220265783A1 (en) Viral conjunctivitis treatment using ranpirnase and/or amphinase
CN101252949A (zh) 促进上皮再生
RU2811435C2 (ru) Рекомбинантные модифицированные факторы роста фибробластов и их терапевтическое применение
JP2022516729A (ja) ロイコトリエン受容体アンタゴニストを含有する新たな製剤
CN102485272A (zh) 重组人Prx-6蛋白在治疗烧烫伤方面的用途
DK2590666T3 (en) TOPICAL APPLICATION OF ERYTHROPOIETIN FOR USE IN THE TREATMENT OF DAMAGE OF THE CORNS
WO2012075911A1 (zh) 重组人prx-6蛋白在治疗烧烫伤和/或角膜损伤中的用途
RU2277413C2 (ru) Способ лечения вторичной дистрофии роговицы
WO2017172525A2 (en) Modified fibroblast growth factors and uses thereof
EP3988122A1 (en) Application of transthyretin in entering eye and preparing drop
JP2008519032A (ja) Ｆｇｆ−２０の調合物、生成方法および使用
HK40030921A (en) Modified fibroblast growth factors-1 for the treatment of ocular disorders
US20140235545A1 (en) The use of HCV immunogenic peptide or a derivative thereof in the prevention or treatment of arthritis
JP2007516223A (ja) 新規線維芽細胞成長因子及びその使用方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191204

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210503

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230821

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240216

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240529

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20240216

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20230821

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I